Merck Announces First Phase Three Studies for PCV-15 (V114) Its Investigational Pneumococcal Disease…
Merck announced that the company is beginning two Phase 3 studies of PCV-15 (V114), its investigational polyvalent conjugate vaccine for the prevention of pneumococcal disease. The…
Read More...
Read More...
